Reimbursement begins slowly for Biogen’s expensive Alzheimer’s drug
Medicare Administrative Contractors, or MACs, are now sporadically reimbursing for Biogen’s expensive new Alzheimer’s drug in limited pockets across the US, as CMS has several …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
